Genome & Company, an immunotherapy developer, has taken the first to jump into the CDMO industry by acquiring a U.S. microbiome company, List Biological Laboratory (List Labs).
At an online news conference on Wednesday, the company presented its mid-to-long-term vision of becoming a fully integrated pharmaceutical company that can conduct research and manufacture products.
Genome & Company will let List Labs run independently, internalize the microbiome pipeline production, and generate sales through the microbiome CDMO business.
List Labs, located in San Jose, Calif., has a 43-year history of producing microbiome and biotoxins. The company is recognized for its quality control capabilities that meet the U.S. Food and Drug Administration’s GMP manufacturing with rich experience in strains for making aerobic and anaerobic microbiome products.
Genome & Company plans to strengthen its ability to provide microbiome CDMO services from phase 1 to 3 clinical trials and commercialization of the medical products. In addition, the company will implement bioreactors and maximize the synergistic effect with List Labs.
“We expect to further strengthen capabilities as a customer-oriented microbiome CDMO with Genome & Company, a global microbiome developer,” List Labs President Stacy Burns-Guydish said. “By combining the capabilities of both companies, we will advance as a global microbiome CDMO leader.”
Genome & Company CEO Bae Ji-soo also said, “We are aiming to become a global pharmaceutical company by developing new drugs with our partner by pioneering underexplored fields, including microbiome-based medical products for cancer immunotherapy, brain disorders, and obstetrics and gynecology.”
Bae added that the company would grow as the first mover in the global microbiome industry by generating additional sales related to the microbiome CDMO business and speeding up the development of pipelines.
During the meeting, Genome & Company expected the global microbiome treatment market to grow with increasing demand for production capacity. The company expected the market to grow by 167 times, from $56.3 million in 2018 to $9.39 billion in 2024.